Evidence map›Paper›PMID 31492872›Full record

ArticleScientific reports2019

Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images.

Jesuchristopher Joseph, Martine P Roudier, Priya Lakshmi Narayanan, Renaldas Augulis, Vidalba Rocher Ros, Alison Pritchard, Joe Gerrard, Arvydas Laurinavicius, Elizabeth A Harrington, J Carl Barrett and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A study on the diagnosis of theFrontiers in microbiology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. AI in Medical Imaging Informatics: Current Challenges and Future Directions.IEEE journal of biomedical and health informatics · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jesuchristopher JosephMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom. jjoseph@coh.org.
Martine P RoudierMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
Priya Lakshmi NarayananCentre for Evolution and Cancer, Division of Molecular Pathology, Institute of Cancer Research London, London, United Kingdom.
Renaldas AugulisVilnius University, Faculty of Medicine and the National Centre of Pathology, affiliate of Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania.
Vidalba Rocher RosMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
Alison PritchardMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
Joe GerrardMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
Arvydas LaurinaviciusVilnius University, Faculty of Medicine and the National Centre of Pathology, affiliate of Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania.
Elizabeth A HarringtonMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
J Carl BarrettMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
William J HowatMolecular Pathology Group, Translational Science, AstraZeneca, Cambridge, United Kingdom.
AstraZeneca (United Kingdom) · GBVilnius University · LTInstitute of Cancer Research · GB

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Uncontrolled proliferation is a hallmark of cancer and can be assessed by labelling breast tissue using immunohistochemistry for Ki67, a protein associated with cell proliferation. Accurate measurement of Ki67-positive tumour nuclei is of critical importance, but requires annotation of the tumour regions by a pathologist. This manual annotation process is highly subjective, time-consuming and subject to inter- and intra-annotator experience. To address this challenge, we have developed Proliferation Tumour Marker Network (PTM-NET), a deep learning model that objectively annotates the tumour regions in Ki67-labelled breast cancer digital pathology images using a convolution neural network. Our custom designed deep learning model was trained on 45 immunohistochemical Ki67-labelled whole slide images to classify tumour and non-tumour regions and was validated on 45 whole slide images from two different sources that were stained using different protocols. Our results show a Dice coefficient of 0.74, positive predictive value of 70% and negative predictive value of 88.3% against the manual ground truth annotation for the combined dataset. There were minimal differences between the images from different sources and the model was further tested in oestrogen receptor and progesterone receptor-labelled images. Finally, using an extension of the model, we could identify possible hotspot regions of high proliferation within the tumour. In the future, this approach could be useful in identifying tumour regions in biopsy samples and tissue microarray images.

Indexed as

Image Processing, Computer-AssistedStaining and LabelingAutomationBiomarkers, TumorBreast NeoplasmsCell ProliferationFemaleHumansKi-67 AntigenNeoplasm InvasivenessReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorKi-67 AntigenReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID31492872
PMCPMC6731323
OpenAlexW2972052510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.